Table 1.
Baseline characteristics
| Characteristic | N = 109* |
|---|---|
| Follow-up (y) | 2.36 (1.54, 3.10) |
| Current smoker | |
| Not smoking | 103 (94%) |
| Smoking | 6 (5.5%) |
| Obese | |
| BMI <30 | 72 (66%) |
| BMI ≥30 | 37 (34%) |
| cT | |
| T0 | 1 (0.9%) |
| T1 | 33 (30%) |
| T2 | 38 (35%) |
| T3 | 27 (25%) |
| T4 | 6 (5.5%) |
| Tis | 4 (3.7%) |
| cN | |
| N0 | 53 (49%) |
| N1 | 49 (45%) |
| N2 | 1 (0.9%) |
| N3 | 6 (5.5%) |
| c Stage | |
| 0 | 4 (3.7%) |
| IA | 25 (23%) |
| IIA | 20 (19%) |
| IIB | 31 (29%) |
| IIIA | 17 (16%) |
| IIIB | 5 (4.6%) |
| IIIC | 6 (5.6%) |
| ypT | |
| T0 | 13 (25%) |
| T1 | 20 (38%) |
| T2 | 12 (23%) |
| T3 | 5 (9.4%) |
| T4 | 1 (1.9%) |
| Tis | 2 (3.8%) |
| ypN | |
| N0 | 21 (40%) |
| N1 | 20 (38%) |
| N1mi | 0 (0%) |
| N2 | 9 (17%) |
| N3 | 3 (5.7%) |
| yp Stage | |
| 0 | 2 (4.8%) |
| IA | 7 (17%) |
| IIA | 11 (26%) |
| IIB | 7 (17%) |
| IIIA | 11 (26%) |
| IIIB | 1 (2.4%) |
| IIIC | 3 (7.1%) |
| pT | |
| T0 | 3 (5.0%) |
| T1 | 20 (33%) |
| T2 | 24 (40%) |
| T3 | 13 (22%) |
| Tis | 0 (0%) |
| pN | |
| N0 | 11 (18%) |
| N1 | 35 (58%) |
| N1mi | 3 (5.0%) |
| N2 | 8 (13%) |
| N3 | 3 (5.0%) |
| p Stage | |
| IA | 3 (5.2%) |
| IB | 3 (5.2%) |
| IIA | 18 (31%) |
| IIB | 17 (29%) |
| IIIA | 14 (24%) |
| IIIC | 3 (5.2%) |
| Age at diagnosis (median, IQR) | 49 (41, 57) |
| Hypertension | 16 (15%) |
| Diabetes | 4 (3.7%) |
| Menopause | |
| Premenopausal | 47 (43%) |
| Perimenopausal | 3 (2.8%) |
| Postmenopausal | 55 (50%) |
| Surgical | 4 (3.7%) |
| Histology | |
| DCIS | 2 (1.8%) |
| IDC | 84 (77%) |
| ILC | 21 (19%) |
| IMC | 2 (1.8%) |
| Receptor status | |
| HR +/HER2– | 82 (75%) |
| HR +/HER2+ | 9 (8.3%) |
| HR +/HER2 unknown | 2 (1.8%) |
| HR–/HER2+ | 8 (7.3%) |
| HR–/HER2– | 8 (7.3%) |
| Type of mastectomy | |
| Nipple sparing | 15 (14%) |
| Skin sparing | 94 (86%) |
| Type of reconstruction | |
| 1 stage | 4 (3.7%) |
| 2 stage | 105 (96%) |
| Axillary surgery type | |
| ALND | 17 (16%) |
| SLN + ALND | 53 (49%) |
| SLN | 38 (35%) |
| Final margin status | |
| Negative | 96 (88%) |
| Positive | 12 (11%) |
| Positive (DCIS) | 1 (0.9%) |
| Sequence of chemotherapy | |
| None | 16 (15%) |
| Adjuvant | 39 (36%) |
| Neoadjuvant | 54 (50%) |
| Herceptin | 18 (17%) |
| Hormones | 86 (80%) |
Abbreviations: ALND = axillary lymph node dissection; BMI = body mass index; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma: ILC = invasive ductal carcinoma; IMC = invasive mammary carcinoma; SLN = sentinel lymph node procedure.
⁎
Median (IQR); no. (%).